GeminIQ

ABT

ABBOTT LABORATORIES
$102.36previous close on: 9/16/2026

Company Information

Company Name
ABBOTT LABORATORIES
CIK
CIK0000001800
Category
Large accelerated filer
Ticker: Exchange
ABT: NYSE
Fiscal Year End
December 31
Owner Organization
03 Life Sciences
SIC
2834
SIC Description
Pharmaceutical Preparations
Ticker
ABT

SEC filing data through

Insider Sentiment

Last purchase
2026-05-07
Last sale
2026-03-02
Shares purchased (TTM)
43,000
Shares sold (TTM)
11,335
Buy ratio (TTM)79.1%

Institutional Sentiment

As of
2026-03-31
Institutional shares owned
1,297,494,961
Shares outstanding
1,742,480,000
Ownership
74.46%
+0.36% Y/Y

Earnings Market Reaction

Filing date
2026-04-29
Price on filing date
—
1-month reaction
-4.29%
3-month reaction
11.02%
Drift continued5/12 (42%)
Faded / reversed7/12 (58%)
Export data

Balance Sheet

Values in millions ($)
Line item2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-30Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only columnTrend
Assets Current
Cash And Cash Equivalents At Carrying Value6,8038,5227,5116,9516,5327,6167,5586,9876,2846,8966,7097,835
Short Term Investments492417222331312351230232367383338320
Accounts Receivable Net Current8,2107,9298,1387,9727,3276,9257,0516,8546,6056,5656,4996,172
Inventory Net
Inventory Finished Goods Net Of Reserves4,2743,9764,1304,3194,0633,7004,1734,0604,0633,9463,8474,004
Inventory Work In Process Net Of Reserves994904961962890840877880881807888845
Inventory Raw Materials Net Of Reserves1,7211,6081,6171,6731,6861,6541,7631,8741,8831,8171,9152,022
Inventory Net6,9896,4886,7086,9546,6396,1946,8136,8146,8276,5706,6506,871
Assets Current25,50825,99624,83924,46823,15323,65623,80223,11922,37622,67022,66423,505
Long Term Investments1,090918951958907886912877818799788799
Property Plant And Equipment Gross
Land-541---528---529--
Buildings And Improvements Gross-4,543---4,207---4,161--
Machinery And Equipment Gross-17,571---15,517---15,179--
Construction In Progress Gross-2,567---2,488---2,064--
Property Plant And Equipment Gross25,73725,22224,81624,47223,41822,74022,85722,06122,05521,93321,11120,926
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment13,36013,40613,31213,07712,48612,08212,23611,82811,94811,77911,55911,477
Property Plant And Equipment Net12,37711,81611,50411,39510,93210,65810,62110,23310,10710,1549,5529,449
Intangible Assets Net Excluding Goodwill17,8755,5265,5985,9206,2616,6477,3527,8278,2968,8159,2829,834
Goodwill35,22124,03523,97123,95223,35923,10823,65823,30823,38323,67923,27723,258
Deferred Income Taxes And Other Assets Noncurrent18,35818,42217,31817,30616,83616,4598,0117,6537,4877,0976,5276,509
Assets110,42986,71384,18183,99981,44881,41474,35673,01772,46773,21472,09073,354
Liabilities Current
Accounts Payable Trade Current4,6794,2404,1234,3064,2144,1954,0344,1254,1784,2953,9614,211
Employee Related Liabilities Current1,2121,7451,7351,5501,1671,7011,6181,3891,0921,5971,4791,362
Other Accrued Liabilities Current6,3795,8125,8805,6565,6005,1435,4275,0715,2205,4225,3475,334
Dividends Payable Current1,1001,0971,0301,0301,0321,024956959959955886886
Accrued Income Taxes Current598569469390485594713601562492318273
Long Term Debt Current4,4093,0331,3455075061,5002,1541,6152,0101,0801,0512,284
Liabilities Current18,37716,49614,58213,43913,00414,15714,90213,76014,02113,84113,04214,350
Long Term Debt Noncurrent29,6389,89611,59612,93012,73612,62512,82513,13912,57613,59914,47714,562
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
Preferred Stock Value000000000000
Common Stock Value25,35225,52725,41225,28425,12525,15325,02024,85824,72624,86924,72724,612
Treasury Stock Common Value-16,935-17,177-16,877-16,610-16,612-16,844-16,476-15,759-15,761-15,981-15,686-15,722
Retained Earnings Accumulated Deficit49,95649,78149,10348,46747,71547,26139,05638,35438,01137,55436,92036,355
Accumulated Other Comprehensive Income Loss Net Of Tax-6,312-6,001-6,684-6,576-7,417-7,906-7,804-8,135-8,166-7,839-8,480-8,071
Stockholders Equity52,06152,77151,26450,82948,81147,90139,79639,31839,04338,82737,69437,404
Minority Interest640641310264253237232242233224213230
Liabilities And Stockholders Equity110,42986,71384,18183,99981,44881,41474,35673,01772,46773,21472,09073,354
Allowance For Doubtful Accounts Receivable Current494490490471449439456441439444472485
Preferred Stock Par Or Stated Value Per Share1.001.001.001.001.001.001.001.001.001.001.001.00
Preferred Stock Shares Authorized111111111111
Preferred Stock Shares Issued000000000000
Common Stock Shares Authorized2,4002,4002,4002,4002,4002,4002,4002,4002,4002,4002,4002,400
Common Stock Shares Issued1,9981,9971,9971,9961,9961,9911,9911,9901,9901,9881,9871,987
Treasury Stock Common Shares256260258256256260257250250254251252

Select a line item above to chart it.

Recent filings

Financial statements beyond 3 years are for subscribers only.

Unlock 17+ years of income statements, balance sheets, and cash flow statements

Start 7-day free trial

ABBOTT LABORATORIES (ABT) — SEC Financial Statements & Analysis

ABBOTT LABORATORIES (ABT) is a pharmaceutical preparations company, incorporated in IL. ABBOTT LABORATORIES trades on NYSE as: ABT. ABBOTT LABORATORIES (ABT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-04-29. Based on that filing, ABBOTT LABORATORIES carries a market cap of $176.53B, a P/E ratio of 28.13x, a P/B ratio of 3.39x, a P/S ratio of 3.91x, an enterprise value of $203.77B, and an EV/EBITDA multiple of 22.19x. On profitability, it posts a gross margin of 56.26%, an operating margin of 17.07%, a net margin of 13.91%, a Return on Equity (ROE) of 12.44%, a Return on Assets (ROA) of 6.54%, and a Return on Invested Capital (ROIC) of 8.70%. Per share, it reports EPS of $3.60, diluted EPS of $3.59, free cash flow per share of $4.23, and a dividend per share of $2.40. Over the trailing year, it posted revenue growth of 6.59% year-over-year, net income growth of -53.52% year-over-year, and EPS growth of -53.61% year-over-year. On the balance sheet, it maintains a current ratio of 1.39x, a quick ratio of 1.01x, working capital of $7.13B, a debt-to-equity ratio of 0.35x, a debt ratio of 0.17, an interest coverage ratio of 14.38x, free cash flow of $7.38B (TTM), and net debt of $27.24B. Figures sourced from SEC EDGAR.

Market Cap
$176.53B
P/E TTM
28.13x
EPS TTM
$3.60
P/B TTM
3.39x
ROE TTM
12.44%
ROA TTM
6.54%
Debt To Equity
0.35x
Free Cash Flow TTM
$7.38B
Net Revenue TTM Growth 1Y
6.59%

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is ABBOTT LABORATORIES in?

ABBOTT LABORATORIES (ABT) operates in the Pharmaceutical Preparations industry.

What exchange does ABT trade on?

ABBOTT LABORATORIES (ABT) trades on the NYSE.

Where is ABBOTT LABORATORIES incorporated?

ABBOTT LABORATORIES is incorporated in IL.

When was ABBOTT LABORATORIES (ABT)'s most recent SEC filing?

ABBOTT LABORATORIES (ABT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-04-29.

What is ABT's market cap?

ABBOTT LABORATORIES (ABT) has a market capitalization of $176.53B as of 2026-03-31.

What is ABT's P/E ratio?

ABBOTT LABORATORIES (ABT)'s trailing twelve month P/E ratio is 28.13x as of 2026-03-31.

What is ABT's EPS (earnings per share)?

ABBOTT LABORATORIES (ABT)'s trailing twelve month EPS is $3.60 as of 2026-03-31.

What is ABT's ROE (return on equity)?

ABBOTT LABORATORIES (ABT)'s trailing twelve month Return on Equity (ROE) is 12.44% as of 2026-03-31.

What is ABT's ROA (return on assets)?

ABBOTT LABORATORIES (ABT)'s trailing twelve month Return on Assets (ROA) is 6.54% as of 2026-03-31.

What is ABT's ROIC (return on invested capital)?

ABBOTT LABORATORIES (ABT)'s trailing twelve month Return on Invested Capital (ROIC) is 8.70% as of 2026-03-31.

What is ABT's EV/EBITDA?

ABBOTT LABORATORIES (ABT)'s trailing twelve month EV/EBITDA is 22.19x as of 2026-03-31.

Wall Street's data.
Main Street's price.

Start 7-day free trial